mitoxantrone has been researched along with Tumor Lysis Syndrome in 4 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Tumor Lysis Syndrome: A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 9.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 5.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| " Mitoxantrone plasma samples were obtained prior to dosing and at 0, 0." | 1.28 | Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis. ( Battaglia, AC; Boros, L; Cacek, T; Pine, RB, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Litzow, MR | 1 |
| Wang, XV | 1 |
| Carroll, MP | 1 |
| Karp, JE | 2 |
| Ketterling, RP | 1 |
| Zhang, Y | 1 |
| Kaufmann, SH | 1 |
| Lazarus, HM | 1 |
| Luger, SM | 1 |
| Paietta, EM | 1 |
| Pratz, KW | 1 |
| Tun, HW | 1 |
| Altman, JK | 1 |
| Broun, ER | 1 |
| Rybka, WB | 1 |
| Rowe, JM | 1 |
| Tallman, MS | 1 |
| Blackford, A | 1 |
| Smith, BD | 1 |
| Alino, K | 1 |
| Seung, AH | 1 |
| Bolaños-Meade, J | 1 |
| Greer, JM | 1 |
| Carraway, HE | 1 |
| Gore, SD | 1 |
| Jones, RJ | 1 |
| Levis, MJ | 1 |
| McDevitt, MA | 1 |
| Doyle, LA | 1 |
| Wright, JJ | 1 |
| van der Jagt, RH | 1 |
| Boros, L | 1 |
| Cacek, T | 1 |
| Pine, RB | 1 |
| Battaglia, AC | 1 |
2 trials available for mitoxantrone and Tumor Lysis Syndrome
| Article | Year |
|---|---|
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival | 2019 |
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2010 |
2 other studies available for mitoxantrone and Tumor Lysis Syndrome
| Article | Year |
|---|---|
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modalit | 2010 |
Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis.
Topics: Aged; Female; Humans; Lymphoma; Mitoxantrone; Renal Dialysis; Renal Insufficiency; Time Factors; Tis | 1992 |